Literature DB >> 19715556

Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10.

Cristina I Caescu1, Grace R Jeschke, Benjamin E Turk.   

Abstract

The metalloproteinases TACE [tumour necrosis factor alpha-converting enzyme; also known as ADAM17 (a disintegrin and metalloproteinase 17)] and ADAM10 are the primary enzymes responsible for catalysing release of membrane-anchored proteins from the cell surface in metazoan organisms. Although the repertoire of protein substrates for these two proteases is partially overlapping, each one appears to target a subset of unique proteins in vivo. The mechanisms by which the two proteases achieve specificity for particular substrates are not completely understood. We have used peptide libraries to define the cleavage site selectivity of TACE and ADAM10. The two proteases have distinct primary sequence requirements at multiple positions surrounding the cleavage site in their substrates, which allowed us to generate peptide substrates that are highly specific for each of these proteases. The major difference between the two protease specificities maps to the P1' position (immediately downstream of the cleavage site) of the substrate. At this position, TACE is selective for smaller aliphatic residues, whereas ADAM10 can accommodate aromatic amino acids. Using mutagenesis we identified three residues in the S1' pockets of these enzymes that dramatically influence specificity for both peptide and protein substrates. Our results suggest that substrate selectivity of TACE and ADAM10 can be at least partly rationalized by specific features of their active sites.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19715556      PMCID: PMC2774824          DOI: 10.1042/BJ20090549

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  58 in total

1.  ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation.

Authors:  Thorsten Maretzky; Karina Reiss; Andreas Ludwig; Julian Buchholz; Felix Scholz; Erhardt Proksch; Bart de Strooper; Dieter Hartmann; Paul Saftig
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-15       Impact factor: 11.205

2.  Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase.

Authors:  Markus P Kummer; Hiroko Maruyama; Claudia Huelsmann; Sandra Baches; Sascha Weggen; Edward H Koo
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

3.  Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis.

Authors:  J Zhao; H Chen; J J Peschon; W Shi; Y Zhang; S J Frank; D Warburton
Journal:  Dev Biol       Date:  2001-04-01       Impact factor: 3.582

4.  Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme.

Authors:  P Reddy; J L Slack; R Davis; D P Cerretti; C J Kozlosky; R A Blanton; D Shows; J J Peschon; R A Black
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

5.  Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins.

Authors:  K Althoff; P Reddy; N Voltz; S Rose-John; J Müllberg
Journal:  Eur J Biochem       Date:  2000-05

6.  A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE.

Authors:  C Brou; F Logeat; N Gupta; C Bessia; O LeBail; J R Doedens; A Cumano; P Roux; R A Black; A Israël
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

7.  A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1.

Authors:  J S Mumm; E H Schroeter; M T Saxena; A Griesemer; X Tian; D J Pan; W J Ray; R Kopan
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

8.  Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins.

Authors:  K Althoff; J Müllberg; D Aasland; N Voltz; K Kallen; J Grötzinger; S Rose-John
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

Review 9.  Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis.

Authors:  Marcia L Moss; Liora Sklair-Tavron; Raphael Nudelman
Journal:  Nat Clin Pract Rheumatol       Date:  2008-04-15

10.  ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.

Authors:  Sylvain M Le Gall; Pierre Bobé; Karina Reiss; Keisuke Horiuchi; Xiao-Da Niu; Daniel Lundell; David R Gibb; Daniel Conrad; Paul Saftig; Carl P Blobel
Journal:  Mol Biol Cell       Date:  2009-01-21       Impact factor: 4.138

View more
  80 in total

1.  ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons.

Authors:  Peer-Hendrik Kuhn; Huanhuan Wang; Bastian Dislich; Alessio Colombo; Ulrike Zeitschel; Joachim W Ellwart; Elisabeth Kremmer; Steffen Rossner; Stefan F Lichtenthaler
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

2.  Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities.

Authors:  Miles A Miller; Layla Barkal; Karen Jeng; Andreas Herrlich; Marcia Moss; Linda G Griffith; Douglas A Lauffenburger
Journal:  Integr Biol (Camb)       Date:  2010-12-23       Impact factor: 2.192

3.  Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates.

Authors:  Roma Stawikowska; Mare Cudic; Marc Giulianotti; Richard A Houghten; Gregg B Fields; Dmitriy Minond
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

4.  VEGF (Vascular Endothelial Growth Factor) Induces NRP1 (Neuropilin-1) Cleavage via ADAMs (a Disintegrin and Metalloproteinase) 9 and 10 to Generate Novel Carboxy-Terminal NRP1 Fragments That Regulate Angiogenic Signaling.

Authors:  Vedanta Mehta; Laura Fields; Ian M Evans; Maiko Yamaji; Caroline Pellet-Many; Timothy Jones; Marwa Mahmoud; Ian Zachary
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

5.  Chemoproteomics of matrix metalloproteases in a model of cartilage degeneration suggests functional biomarkers associated with posttraumatic osteoarthritis.

Authors:  Kodihalli C Ravindra; Caroline C Ahrens; Yang Wang; Julie Y Ramseier; John S Wishnok; Linda G Griffith; Alan J Grodzinsky; Steven R Tannenbaum
Journal:  J Biol Chem       Date:  2018-05-23       Impact factor: 5.157

6.  A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3).

Authors:  Katja Möller-Hackbarth; Christin Dewitz; Olga Schweigert; Ahmad Trad; Christoph Garbers; Stefan Rose-John; Jürgen Scheller
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

Review 7.  ADAM-17: the enzyme that does it all.

Authors:  Monika Gooz
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

8.  Domain integration of ADAM family proteins: Emerging themes from structural studies.

Authors:  Tom Cm Seegar; Stephen C Blacklow
Journal:  Exp Biol Med (Maywood)       Date:  2019-07-23

9.  Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype.

Authors:  Will S Driscoll; Tomas Vaisar; Jingjing Tang; Carole L Wilson; Elaine W Raines
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

10.  Mapping and functional characterization of murine kidney injury molecule-1 proteolytic cleavage site.

Authors:  Saranga Sriranganathan; Elena Tutunea-Fatan; Alina Abbasi; Lakshman Gunaratnam
Journal:  Mol Cell Biochem       Date:  2020-11-19       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.